search
Back to results

The TARGET-EFT Randomized Clinical Trial (TARGET-EFT)

Primary Purpose

Frailty, Cardiovascular Diseases in Old Age, Geriatric Cardiology

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Physical Component of the Intervention
Cognitive Component of the Intervention
Nutritional Component of the Intervention
Iron-Deficiency Anemia (IDA) Component of the Intervention
Sponsored by
Jonathan Afilalo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frailty focused on measuring Randomized Clinical Trial, Frailty, Intervention

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥65 years
  • Frail or pre-frail as defined by EFT score ≥1
  • Admission to the JGH cardiovascular unit
  • Signed informed consent

Exclusion Criteria:

  • Expected discharge within <3 days
  • Clinically unstable (unstable vital signs, low-threshold coronary ischemia, uncontrolled heart failure, uncontrolled arrhythmia)
  • Awaiting cardiac surgery during the index hospitalization
  • Severe dementia (MMSE ≤10/30)
  • Delirium (CAM positive)
  • Psychiatric condition precluding cooperation
  • Not English or French speaking
  • Parkinson's disease
  • Recent stroke <7 days
  • Bed-bound or paraplegic
  • End-of-life care plan

Sites / Locations

  • Jewish General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control Group

Intervention Group

Arm Description

Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.

Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.

Outcomes

Primary Outcome Measures

Change in health-related quality of life: EQ-5D-5L scale
Self-reported health-related quality of life is measured with EQ-5D at baseline and discharge. Items are scored level 1-5 (1 = no problems, 5 = unable/extreme problems). The visual analog scale is scored 0-100 (0 = worse imaginable health ever, 100 = best imaginable health ever). The scale generates a descriptive set that is compared to value sets to produce a value index.

Secondary Outcome Measures

Change in health-related quality of life: EQ-5D-5L scale
Self-reported health-related quality of life is measured with EQ-5D at 30-days post-hospitalization. Items are scored level 1-5 (1 = no problems, 5 = unable/extreme problems). The visual analog scale is scored 0-100 (0 = worse imaginable health ever, 100 = best imaginable health ever). The scale generates a descriptive set that is compared to value sets to produce a value index.
Change in Hospital-Acquired disability
Hospital-acquired disability will be measured using the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. ADLs will be assessed at baseline and discharge. Each item is scored 1-3 (1 = without help, 3 = completely unable to), yielding a total score of 0-7.
Hospital-acquired disability
Hospital-acquired disability will be measured using the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. ADLs will be assessed at 30-days post-hospitalization. Each item is scored 1-3 (1 = without help, 3 = completely unable to), yielding a total score of 0-7.
Number of participants with all-cause death, delirium, fall, infection, pressure ulcer
Composite endpoint
Number of participants with all-cause death, discharge to healthcare facility, unplanned repeat hospital visit
Composite endpoint
Length of stay
Number of days from cardiovascular unit admission to hospital discharge.
Time out of bed
Average number of hours per day out of bed recorded by actigraphy
Lower extremity physical performance
Lower extremity weakness will be assessed using the Short Physical Performance Battery scale (SPPB) at baseline and discharge. SPPB is scored 0-12 (0 = worst physical performance, 12 = best physical performance).

Full Information

First Posted
January 9, 2020
Last Updated
March 17, 2022
Sponsor
Jonathan Afilalo
search

1. Study Identification

Unique Protocol Identification Number
NCT04291690
Brief Title
The TARGET-EFT Randomized Clinical Trial
Acronym
TARGET-EFT
Official Title
The TARGET-EFT Trial (MulTicomponent Acute Intervention in FRail GEriatric PaTients With Cardiovascular Disease Using the Essential Frailty Toolset)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
March 5, 2020 (Actual)
Primary Completion Date
September 24, 2021 (Actual)
Study Completion Date
September 24, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jonathan Afilalo

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Randomized clinical trial to determine whether a multicomponent intervention will lead to improvements in mobility, self-care, mood, pain, and physical activity among frail and pre-frail older adults (as measured with the Essential Frailty Toolset; EFT) hospitalized for an acute cardiovascular illness.
Detailed Description
The investigators will conduct a single-center randomized clinical trial at the Jewish General Hospital; an academic tertiary care center in Montreal, Quebec. Researchers will pre-screen stable patients ≥65 years of age admitted to the cardiovascular unit. The investigators will target those that consent and have evidence of frailty or pre-frailty according to the EFT (score ≥1/5). The EFT consists of a chair rise test to screen for physical frailty, a mini-cog test to screen for cognitive impairment, a hemoglobin level and a serum albumin level. Patients will be randomly allocated to the usual-care control group, or the intervention group that will receive targeted treatments depending on the EFT deficits identified. All patients will be outfitted with a hip-worn accelerometer to monitor position, step count, and sleep data during the study period. Patients will undergo a structured questionnaire and physical performance assessment at baseline (upon index admission) and at discharge, and will be contacted by telephone 30 days post-discharge to assess their recovery. The primary endpoint will be represented by the EQ-5D scale (mobility, self-care, mood, pain, and physical activity) measured by blinded observers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frailty, Cardiovascular Diseases in Old Age, Geriatric Cardiology, Quality of Life
Keywords
Randomized Clinical Trial, Frailty, Intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-center randomized clinical trial with parallel group design at the Jewish General Hospital (JGH); an academic tertiary care center in Montreal, Quebec, Canada.
Masking
Outcomes Assessor
Masking Description
Outcome assessors will be blinded to the allocated group of the patients, and they will not be the same team members that delivered the intervention.
Allocation
Randomized
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Usual clinical care as prescribed by their treating clinicians; which may or may not include physiotherapy, geriatric consultation, nutritional consultation and supplementation, and treatment of anemia.
Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Multi-component intervention in addition to usual care; which may include - in a targeted fashion - physical training for those with physical weakness, cognitive stimulation for those with cognitive impairment, oral nutritional supplementation for those with malnutrition, and intravenous iron replacement therapy for those with iron deficiency anemia.
Intervention Type
Other
Intervention Name(s)
Physical Component of the Intervention
Intervention Description
We will encourage and assist patients to walk around the ward as tolerated and approved by their treating clinicians, to maximize the time spent out of bed, minimize the time spent in bed, and to encourage and assist them to perform chair rises to build lower extremity strength. For selected intervention patients with greater physical weakness, defined as SPPB ≤9, a Certified Exercise Physiologist will administer a supervised multicomponent exercise program combining strength, flexibility, balance and gait for the prevention of weakness and falls. The exercise program is adapted from the Vivifrail program which is an EU-funded initiative that provides a guide to prevent frailty, physical deconditioning, and incident disability in older persons. The program includes two daily sessions, one in the morning and one in the afternoon, for a duration of 20 minutes each. The morning session includes strength and flexibility exercises. The afternoon session targets balance and walking.
Intervention Type
Other
Intervention Name(s)
Cognitive Component of the Intervention
Intervention Description
We will encourage and assist them to wear their hearing and visual aids (if they have these), orient them to time and place verbally and in writing on a clearly visible white-board in their hospital room - and also encourage their family members and caregivers to do so on a regular basis, and inquire about their sleep quality and communicate with the clinical team to reduce sleep disturbances. For selected intervention patients with greater cognitive impairments, defined as MMSE ≤26, we will provide cognitive simulation twice daily during the scheduled visits. Cognitive stimulation comprises of activities with the patient, including but not limited to current news, trivia, crossword puzzles, and memory games. These cognitive interventions are adapted from the Hospital Elder Life Program (HELP) that targets risk factors for delirium.
Intervention Type
Other
Intervention Name(s)
Nutritional Component of the Intervention
Intervention Description
We will reinforce proper eating habits, encourage and assist patients to wear their dentures (if they have these), and inquire about their food preferences and eating barriers and communicate with the clinical dieticians to address these issues. For selected intervention patients with greater nutritional deficits, defined as a positive PONS, we will recommend to the treating clinicians to prescribe MedPass supplementation. PONS, developed as a preoperative screening tool but also used in nonoperative medical settings, reflects low body mass index, weight loss, low dietary intake, and albumin level. MedPass is a 60 mL calorically dense (2 kcal/mL) oral nutritional supplement consumed between meals 4 times per daily. If MedPass supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative supplementation strategies.
Intervention Type
Other
Intervention Name(s)
Iron-Deficiency Anemia (IDA) Component of the Intervention
Intervention Description
We will verify their clinical blood test results for hemoglobin level and iron studies and apply the diagnostic criteria for iron deficiency as recommended by the Canadian Cardiovascular Society Guidelines for Heart Failure. These criteria are: (i) Hemoglobin <130g/L in men or <120g/L in women with (ii) a Ferritin <100μg/L or a Ferritin <300μg/L with a Saturation <20%. For selected intervention patients with diagnosed iron deficiency anemia, according to these established criteria, we will recommend to the treating clinicians to prescribe Venofer intravenous iron replacement therapy. The use of intravenous iron replacement therapy is a Strong Recommendation in the Canadian Cardiovascular Society Guidelines. Venofer is prescribed at a dosage of 300 mg IV daily for a total of 3 doses. If Venofer supplementation is contraindicated, the treating team will have the full discretion not to prescribe it and/or to consider alternative strategies.
Primary Outcome Measure Information:
Title
Change in health-related quality of life: EQ-5D-5L scale
Description
Self-reported health-related quality of life is measured with EQ-5D at baseline and discharge. Items are scored level 1-5 (1 = no problems, 5 = unable/extreme problems). The visual analog scale is scored 0-100 (0 = worse imaginable health ever, 100 = best imaginable health ever). The scale generates a descriptive set that is compared to value sets to produce a value index.
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Secondary Outcome Measure Information:
Title
Change in health-related quality of life: EQ-5D-5L scale
Description
Self-reported health-related quality of life is measured with EQ-5D at 30-days post-hospitalization. Items are scored level 1-5 (1 = no problems, 5 = unable/extreme problems). The visual analog scale is scored 0-100 (0 = worse imaginable health ever, 100 = best imaginable health ever). The scale generates a descriptive set that is compared to value sets to produce a value index.
Time Frame
From date of hospital discharge (assessed up to 6-weeks) to 30-days post-discharge (assessed up to 10 weeks)
Title
Change in Hospital-Acquired disability
Description
Hospital-acquired disability will be measured using the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. ADLs will be assessed at baseline and discharge. Each item is scored 1-3 (1 = without help, 3 = completely unable to), yielding a total score of 0-7.
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Hospital-acquired disability
Description
Hospital-acquired disability will be measured using the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. ADLs will be assessed at 30-days post-hospitalization. Each item is scored 1-3 (1 = without help, 3 = completely unable to), yielding a total score of 0-7.
Time Frame
From date of hospital discharge (assessed up to 6-weeks) to 30-days post-discharge (assessed up to 10 weeks)
Title
Number of participants with all-cause death, delirium, fall, infection, pressure ulcer
Description
Composite endpoint
Time Frame
Date of randomization until date of first documented progression of all-cause death, delirium, fall, infection, pressure ulcer assessed up to hospital discharge (assessed up to 6-weeks)
Title
Number of participants with all-cause death, discharge to healthcare facility, unplanned repeat hospital visit
Description
Composite endpoint
Time Frame
Date of hospital discharge (assessed up to 6-weeks) until date of first documented progression of all-cause death, discharge to healthcare facility, unplanned repeat hospital visit assessed up to 30-days from hospital discharge
Title
Length of stay
Description
Number of days from cardiovascular unit admission to hospital discharge.
Time Frame
Date of cardiovascular unit admission to hospital discharge (assessed up to 6-weeks)
Title
Time out of bed
Description
Average number of hours per day out of bed recorded by actigraphy
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Lower extremity physical performance
Description
Lower extremity weakness will be assessed using the Short Physical Performance Battery scale (SPPB) at baseline and discharge. SPPB is scored 0-12 (0 = worst physical performance, 12 = best physical performance).
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Other Pre-specified Outcome Measures:
Title
Frailty
Description
Frailty will be assessed using the Essential Frailty Toolset (EFT) scale during hospital stay. Each item is scored from 0-2 points, yielding a total score of points 0-5.
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Frailty
Description
Sarcopenia will be assessed with the SARC-F scale at 30 days post-hospital discharge. Each item is scored 0-2 (0 = none, 2 = a lot or unable), yielding a total score of 0-10.
Time Frame
From date of hospital discharge (assessed up to 6-weeks) to 30-days post-discharge (assessed up to 10 weeks)
Title
Mobility
Description
Mobility during hospital stay will be measured using the Level of Function (LOF) scale. LOF is scored level 0-5 (0 = not responsive, not able to cooperate in care and is bed-bound, 5 = able to tolerate increased distances in walking around the unit).
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Change in skeletal muscle mass
Description
Skeletal muscle mass will be measured using a portable bioimpedance and/or ultrasound devices at baseline and discharge.
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Step counts
Description
Physical activity will be measured during the hospital stay. Average number of steps per day are recorded by actigraphy.
Time Frame
Date of randomization to hospital discharge (assessed up to 6-weeks)
Title
Anxiety and depression
Description
Self-reported hospital anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS) at discharge. Items scored 0-3 (0 = no sign of anxiety/depression, 3 = signs of extreme anxiety/depression), yielding a total score of 0-21 for anxiety and depression.
Time Frame
Hospital discharge (assessed up to 6-weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥65 years Frail or pre-frail as defined by EFT score ≥1 Admission to the JGH cardiovascular unit Signed informed consent Exclusion Criteria: Expected discharge within <3 days Clinically unstable (unstable vital signs, low-threshold coronary ischemia, uncontrolled heart failure, uncontrolled arrhythmia) Awaiting cardiac surgery during the index hospitalization Severe dementia (MMSE ≤10/30) Delirium (CAM positive) Psychiatric condition precluding cooperation Not English or French speaking Parkinson's disease Recent stroke <7 days Bed-bound or paraplegic End-of-life care plan
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan Afilalo, MD, MSc
Organizational Affiliation
Jewish General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jewish General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T1E2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The TARGET-EFT Randomized Clinical Trial

We'll reach out to this number within 24 hrs